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ABSTRACT
Objective To determine if pre-eclampsia is associated
withreducedthyroidfunctionduringandafterpregnancy.
Design Nested case-control study during pregnancy and
population based follow-up study after pregnancy.
Setting Calcium for Pre-eclampsia Prevention trial of
healthy pregnant nulliparous women in the United States
during 1992-5, and a Norwegian population based study
(Nord-Trondelag Health Study or HUNT-2) during 1995-7
with linkage to the medical birth registry of Norway.
ParticipantsAll141women(cases)intheCalciumforPre-
eclampsia Prevention trial with serum measurements
before 21 weeks’ gestation (baseline) and after onset of
pre-eclampsia (before delivery), 141 normotensive
controls with serum measurements at similar gestational
ages, and 7121 women in the Nord-Trondelag Health
Study whose first birth had occurred in 1967 or later and
inwhomserumlevelsofthyroidstimulatinghormonehad
been subsequently measured.
Main outcome measures Thyroid function tests and
human chorionic gonadotrophin and soluble fms-like
tyrosine kinase 1 concentrations in the Calcium for Pre-
eclampsia Prevention cohort and odds ratios for levels of
thyroid stimulating hormone above the reference range,
according to pre-eclampsia status in singleton
pregnancies before the Nord-Trondelag Health Study.
Results In predelivery specimens of the Calcium for Pre-
eclampsia Prevention cohort after the onset of pre-
eclampsia, thyroid stimulating hormone levels increased
2.42 times above baseline compared with a 1.48 times
increase in controls. The ratio of the predelivery to
baseline ratio of cases to that of the controls was 1.64
(95% confidence interval 1.29 to 2.08). Free
triiodothyronine decreased more in the women with pre-
eclampsia than in the controls (case ratio to control ratio
0.96, 95% confidence interval 0.92 to 0.99). The
predelivery specimens but not baseline samples from
women with pre-eclampsia were significantly more likely
thanthosefromcontrolstohaveconcentrationsofthyroid
stimulatinghormoneabovethereferencerange(adjusted
odds ratio 2.2, 95% confidence interval 1.1 to 4.4). Both
in women who developed pre-eclampsia and in
normotensive controls the increase in thyroid stimulating
hormoneconcentrationbetweenbaselineandpredelivery
specimens was strongly associated with increasing
quarters of predelivery soluble fms-like tyrosine kinase 1
(P for trend 0.002 and <0.001, respectively). In the Nord-
Trondelag Health Study, women with a history of pre-
eclampsia in their first pregnancy were more likely than
other women (adjusted odds ratio 1.7, 95% confidence
interval 1.1 to 2.5) to have concentrations of thyroid
stimulating hormone above the reference range (>3.5
mIU/l). In particular, they were more likely to have high
concentrations of thyroid stimulating hormone without
thyroid peroxidase antibodies (adjusted odds ratio 2.6,
95% confidence interval 1.3 to 5.0), suggesting
hypothyroid function in the absence of an autoimmune
process. This association was especially strong (5.8, 1.3
to25.5)ifpre-eclampsiahadoccurredinboththefirstand
the second pregnancies.
Conclusion Increased serum concentration of soluble
fms-like tyrosine kinase 1 during pre-eclampsia is
associated with subclinical hypothyroidism during
pregnancy. Pre-eclampsia may also predispose to
reduced thyroid function in later years.
INTRODUCTION
Pre-eclampsia, a pregnancy specific syndrome charac-
terised by new onset hypertension and proteinuria,
causes substantial morbidity and mortality in mothers
and infants.
12Women with a history of pre-eclampsia
have an increased risk of dyslipidaemia, hypertension,
and cardiovascular and renal disease.
3-6
Although the cause of pre-eclampsia is still unclear,
studiesinbothhumansandanimalssuggestthatexcess
circulating antiangiogenic factors such as soluble fms-
like tyrosine kinase 1 (sFlt-1 or sVEGFR1) may be
responsible for the clinical phenotype of pre-
eclampsia.
7-9 Blood concentrations of soluble fms-like
tyrosinekinase1increaseduringthelasttwomonthsof
normal pregnancy and increase to much greater levels
in women with pre-eclampsia. Soluble fms-like
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thelial growth factor and placental growth factor sig-
nalling. Indeed, the use of vascular endothelial
growth factor inhibitors for the treatment of cancer
related angiogenesis has been associated with hyper-
tension, proteinuria, glomerular endothelial damage,
increased concentrations of circulating liver enzymes,
cerebral oedema, and reversible posterior leucoence-
phalopathy—a constellation of conditions resembling
those found in women with pre-eclampsia or
eclampsia.
1011
More recently, patients with cancer who had
received prolonged therapy with vascular endothelial
growthfactorinhibitorswerefoundtobeatgreaterrisk
of hypothyroidism.
12-14 Furthermore, studies in mice
using vascular endothelial growth factor inhibitors
such as soluble fms-like tyrosine kinase 1 have shown
substantial thyroid capillary regression and increased
concentrations of thyroid stimulating hormone.
1115
We therefore hypothesised that the excess soluble
fms-like tyrosine kinase 1 accompanying pre-eclamp-
sia might be associated with reduced thyroid function
during pregnancy and that women who have experi-
enced pre-eclampsia would have an increased risk of
hypothyroid function later in life.
To compare thyroid function in women who devel-
oped pre-eclampsia with those who remained normo-
tensiveduringpregnancy,wecarriedoutanestedcase-
control study within the Calcium for Pre-eclampsia
Prevention (CPEP) trial cohort. We hypothesised that
womenwithpre-eclampsiawouldexperienceagreater
increaseinthyroidstimulatinghormoneconcentration
duringpregnancythannormotensivecontrolsandthat
theextentoftheincreasewouldcorrelatewiththemag-
nitudeofthesolublefms-liketyrosinekinase1concen-
tration during pre-eclampsia. In addition, we used a
Norwegian population based cohort study (the Nord-
Trondelag Health Study or HUNT-2) to test whether
pre-eclampsia in a previous pregnancy is associated
with risk of reduced thyroid function in later life.
Calcium for Pre-eclampsia Prevention trial
Participants and specimens
The Calcium for Pre-eclampsia Prevention trial was a
randomised,doubleblindclinicaltrialcarriedout dur-
ing 1992-5 in healthy nulliparous women with single-
ton pregnancies to evaluate the effects of daily
supplementation with calcium or placebo on the inci-
dence and severity of pre-eclampsia.
1617 Calcium sup-
plementation did not reduce the incidence or severity
of pre-eclampsia or delay its onset.
Ofthe4589womenenrolledinthetrialweexcluded
300 with incomplete information on outcomes or
whose pregnancy ended before 21 weeks. Of 326
women who developed pre-eclampsia, 141 had at
least one serum specimen collected before 21 weeks’
gestation (baseline specimen) and one collected after
the onset of pre-eclampsia (predelivery specimen). If
awomanhadmorethanonespecimencollectedwithin
each of these intervals, we selected the earliest before
21weeksandthelatestaftertheonsetofpre-eclampsia.
Solublefms-liketyrosinekinase1hadpreviouslybeen
analysedinallserumspecimensofarandomsampleof
2200 women and in all women with pre-eclampsia.
18
After excluding women with pre-eclampsia, gesta-
tional hypertension, or gestational proteinuria, 1649
women remained who had been normotensive and
without proteinuria during their pregnancies (con-
trols). Each case of pre-eclampsia was matched to the
control with two serum specimens that were closest in
gestation to the two case specimens. Two case speci-
mens—one baseline, one predelivery—were not
located in the specimen repository.
Women with active dysfunction of the thyroid that
required drugs were excluded from the Calcium for
Pre-eclampsia Prevention trial except those with
hypothyroidism who were stable while receiving thyr-
oidreplacementtherapy.Acheckofdrugsreportedby
the participants of this study showed that only one
woman (who later developed pre-eclampsia) had
received thyroxine. This woman had subclinical
hypothyroidism at baseline, but concentrations of
thyroid stimulating hormone and free thyroxine in
her predelivery specimen were within clinical refer-
ence ranges.
Pre-eclampsia was defined as hypertension—that is,
a diastolic blood pressure of at least 90 mm Hg on two
occasions four to 168 hours apart—and proteinuria,
characterised as one of the following: urine dipstick
results of at least + (30 mg/dl) on two occasions four
to 168 hours apart; a protein to creatinine ratio of at
least 0.35; urine dipstick results of at least ++
(100 mg/dl), or a 24 hour urine specimen containing
at least 300 mg of protein. Detailed definitions have
been published previously.
1617
Procedures
We randomly ordered archived serum specimens,
which had been stored at −70°C, for analysis. Assays
were carried out by staff who were unaware of the out-
come of the pregnancy. Enzyme linked immunosor-
bent assays for human soluble fms-like tyrosine
kinase 1 had previously been done in duplicate by
R&D Systems Analytical TestingServices (Minneapo-
lis,MN,USA).
18Thyroidfunctiontests(thyroidstimu-
lating hormone, free thyroxine, free triiodothyronine,
thyroid peroxidase antibodies) were carried out and
human chorionic gonadotrophin measured using a
Roche Diagnostics Modular Analytics E170 analyzer
(Roche Diagnostics, Indianapolis, IN, USA). Human
chorionic gonadotrophin was measured because it is
known to stimulate the thyroid gland and to decrease
concentrations of thyroid stimulating hormone.
19 The
Roche human chorionic gonadotrophin assay shows
no cross reactivity with thyroid stimulating hormone.
Coefficients of variation in normal serum in mid-preg-
nancy were less than 5%. Reference ranges for thyroid
stimulating hormone (mIU/l) provided by the manu-
facturer were 0.33-4.60, 0.35-4.10, and 0.21-3.15 in
sera from the first, second, and third trimester, respec-
tively.Theupperlimitsofthereferencerangesforthyr-
oid peroxidase antibodies (IU/ml) provided by the
RESEARCH
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20
Women with values above the reference range were
considered to have tested positive for thyroid peroxi-
dase antibodies.
Statistical analysis
We compared categorical variables using the χ
2 test
and continuous variables using t tests. The geometric
meansofthyroidstimulatinghormone,freethyroxine,
free triiodothyronine, and human chorionic gonado-
trophin and their standard deviations are reported for
baseline and predelivery specimens for both cases and
controls. Comparisons of cases and controls are pre-
sented as two tailed P values. Statistical comparisons
of specimens from cases and controls were carried
out using linear models, adjusting for age, body mass
index, race or ethnicity (black people v others), smok-
ing status (current smoker or quit during pregnancy v
never smoker or quit before pregnancy), human chor-
ionic gonadotrophin concentration, and presence of
thyroid peroxidase antibodies above the reference
range. The levels of change from baseline to predeliv-
ery are presented as ratios. Geometric means of the
ratios and their standard deviations are given. We pre-
sentthecomparisonstatisticbetweencaseandcontrol,
which is the ratio of their geometric means, with its
95% confidence interval.
Results
Characteristics of the women
Of the 141 women with pre-eclampsia, 63 (42%) had
severe pre-eclampsia and in 47 (33%) pre-eclampsia
began before 37 weeks’ gestation (table 1). Compared
with the controls, women with pre-eclampsia had a
greater body mass index and higher blood pressure at
thetimeofenrolmentintheCalciumforPre-eclampsia
Preventiontrial.Moreover,alargerproportionoftheir
currentpregnancieshad been complicatedby preterm
delivery or had resulted in the delivery of small for
gestational age infants (table 1). The difference in
gestational age between baseline and predelivery spe-
cimensincasesandcontrolsdidnotdiffersignificantly
(154 v 148 days, P=0.08).
With one exception the characteristics of the 141
women with pre-eclampsia and their infants from the
CalciumforPre-eclampsiaPreventiontrialincludedin
this study (table 1) did not differ significantly from
those of the 185 women with pre-eclampsia and their
infants who had not been included owing to lack of
specimens: infants of the women who had been
included were more often delivered preterm (28% v
16%, P=0.006).
Thyroid function tests and pre-eclampsia
The mean values of thyroid function tests at baseline
were not significantly different (table 2). However,
aftertheonsetofpre-eclampsia,concentrationsofthyr-
oid stimulating hormone and human chorionic gona-
dotrophin were higher in cases than in controls. The
magnitude of the increase in thyroid stimulating hor-
moneconcentrationfrombaselinetopredelivery(pre-
delivery to baseline ratio) was greater in cases than in
controls (table 2); case ratio to control ratio 1.64 (95%
confidenceinterval1.29to2.08).Comparedwithbase-
line specimens, levels of free triiodothyronine were
lower in predelivery specimens, and the magnitude of
the decrease was significantly greater in cases than in
controls (predelivery to baseline ratio 0.85 v 0.89, case
ratio to control ratio 0.96, 0.92 to 0.99). Although free
thyroxine concentrations were also lower in predeliv-
eryspecimensthaninbaselinespecimens,thedecrease
was similar between cases and controls.
The distribution of test results for thyroid function
among cases and controls at baseline and before deliv-
erywasexaminedinrelationtothegestationalagespe-
cific reference ranges for pregnant women. This was
done to determine whether subgroups of the women
who developed pre-eclampsia might have concentra-
tions of thyroid hormones indicating the potential for
clinicallysignificantthyroidmalfunction.Onlythedis-
tributions of thyroid stimulating hormone concentra-
tion were significantly different between cases and
controls. At baseline the proportion of women with
thyroid stimulating hormone concentrations above
the reference range did not differ between women
who would later develop pre-eclampsia and controls
Table 1 |Characteristics of women with pre-eclampsia and controls at enrolment in Calcium
for Pre-eclampsia Prevention trial and characteristics of their infants and specimens*. Values
are numbers (percentages) unless stated otherwise
Characteristics
Cases
(n=141)
Controls
(n=141) P value
Women
Mean (SD) age (years) 20.9 (4.0) 20.1 (3.8) 0.09
Mean (SD) height (cm) 161 (7) 162 (8) 0.08
Mean (SD) weight (kg) 71.9 (19.0) 65.3 (15.4) 0.002
Mean (SD) body mass index† 27.7 (6.9) 24.7 (5.2) <0.001
Mean (SD) systolic blood pressure (mm Hg) 111 (8) 107 (9) <0.001
Mean (SD) diastolic blood pressure (mm Hg) 63 (8) 60 (8) 0.003
Mean (SD) gestational age at enrolment (weeks) 17.4 (2.6) 17.5 (2.5) 0.94
Current smoker 11 (8) 23 (16) 0.03
Calcium treatment 62 (44) 64 (45) 0.81
Private health insurance 8 (6) 12 (9) 0.35
Ever married 33 (23) 27 (19) 0.38
Race or ethnic group‡:
White, non-Hispanic 35 (24.8) 56 (39.7)
0.02
White, Hispanic 19 (13.5) 24 (17.0)
Black 81 (57.5) 58 (41.1)
Other or unknown 6 (4.3) 3 (2.1)
Infants
Mean (SD) birth weight (g) 2964 (816) 3290 (410) <0.001
Delivery at <37 weeks 40 (28.4) 3 (2.1) <0.001
Small for gestational age (<10th centile)§ 25 (17.7) 8 (5.7) 0.002
Specimens
Mean (range) gestational age of baseline specimen (days) 111 (42-146) 112 (49-147) 0.45
Mean(range) gestationalageofpredelivery specimen(days) 265(156-296) 260(166-292) 0.04
*P values are given only for significant differences.
†Weight (kg)/(height (m)
2).
‡Self reported.
§According to US tables that account for race, parity, and sex of infants.
21
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age, body mass index, race, smoking, logarithmically
transformed human chorionic gonadotrophin concen-
tration, and the presence or absence of thyroid perox-
idise antibodies). However, before delivery the
proportion with thyroid stimulating hormone concen-
trations above the reference range was greater in the
women with pre-eclampsia than in the controls: 24%
of cases and 14% of controls (arithmetic means 4.47
mIU/l and 4.26 mIU/l) had thyroid stimulating hor-
mone concentrations above the reference range
(adjusted P=0.03). In predelivery specimens, but not
at baseline, women with pre-eclampsia were signifi-
cantlymorelikelythancontrolstohaveconcentrations
of thyroid stimulating hormone above the reference
range(adjustedoddsratio2.2,95%confidenceinterval
1.1 to 4.4).
Of the 140 women with subsequent pre-eclampsia
and 140 controls tested for thyroid peroxidase anti-
bodies at baseline, six (4%) in each group had positive
results—that is, had levels above the reference range.
In predelivery specimens, seven (5%) cases and four
(3%) controls had positive results. The distributions
of women with thyroid peroxidase antibodies above
the upper limit of the reference range did not differ
significantly between the women who developed pre-
eclampsia and the normotensive controls.
At baseline none of the women had clinical
hypothyroidismasdefinedbythyroidstimulatinghor-
mone concentration above the reference range and
free thyroxine below. However, in predelivery speci-
menstwowomenhaddevelopedclinicalhypothyroid-
ism(thyroidstimulatinghormone5.46and7.33mIU/l
and free thyroxine 8.0 and 8.2 pmol/l), both after the
onset of pre-eclampsia.
Differences in thyroid stimulating hormone concentrations
across quarters of soluble fms-like tyrosine kinase 1
concentrations
To investigate mechanisms by which pre-eclampsia
may be associated with the development of hypothyr-
oidism, the differences between predelivery and
baseline values of thyroid function tests were exam-
ined according to quarters of soluble fms-like tyrosine
kinase 1 concentrations in the predelivery specimens.
Cases and controls were analysed separately. Among
controls the increase in thyroid stimulating hormone
concentrationbetweenbaselineandpredeliveryspeci-
menswasstronglyassociated(Pfortrend<0.001)with
increasing quarters of predelivery soluble fms-like tyr-
osine kinase 1 concentration: arithmetic means 0.01
(SD 1.14) mIU/l, 0.66 (1.04), 0.52 (0.75), and 0.92
(0.91), respectively (figure). The arithmetic mean of
thedifferenceinfreethyroxineconcentrationbetween
predelivery and baseline specimens was greater in the
fourth quarter than in the first quarter (−2.70 v −1.67
pmol/l, P=0.03); but the test for trend was not signifi-
cant. None of the other differences in thyroid function
testresultsorthedifferencesinhumanchorionicgona-
dotrophinconcentrationwereassociatedwithquarters
ofsolublefms-liketyrosinekinase1inpredeliveryspe-
cimens.
Among the cases with pre-eclampsia, the increasein
thyroid stimulating hormone concentration between
baseline and predelivery specimens was also strongly
associated (P for trend 0.002) with increasing quarters
of predelivery soluble fms-like tyrosine kinase: arith-
metic means, respectively, 0.51 (SD 1.12) mIU/l, 0.94
(1.13)mIU/l,1.41(1.32)mIU/l,and1.33(1.29)mIU/l.
Compared with controls, the increase in the pre-
eclampsia group was consistently greater in each cor-
responding quarter. Differences between predelivery
and baseline specimens for the other thyroid function
testsandforhumanchorionicgonadotrophinwerenot
associated with quarters of soluble fms-like tyrosine
kinase 1 concentration in predelivery specimens.
Nord-Trondelag Health Study
Participants and specimens
Between 1995 and 1997 all inhabitants 20 years and
older in Nord-Trondelag county in Norway were
invited to participate in the Nord-Trondelag Health
Study (HUNT-2).
22 Nord-Trondelag county is charac-
terised by a stable and ethnically homogeneous
Table 2 |Results of thyroid function test in baseline and predelivery specimens and predelivery to baseline ratio in cases and controls. Values are geometric
means (standard deviations) unless stated otherwise
Variables
Baseline Predelivery Predelivery to baseline ratio*
Controls Cases P value† Controls Cases P value† Controls Cases
Case ratio to control
ratio (95% CI)
No of women 140 140 — 140 140 141 139 —
Gestational age (days)‡ 112 (20) 111 (20) 0.92 260 (18) 265 (22) 0.04 —— —
TSH (mIU/l) 1.22 (0.27) 0.99 (0.22) 0.14 2.44 (0.67) 3.15 (0.83) 0.007 1.48 (0.11) 2.42 (0.24) 1.64 (1.29 to 2.08)
Free T4 (pmol/l) 13.87 (0.41) 13.81 (0.41) 0.81 12.30 (0.82) 12.10 (0.77) 0.45 0.86 (0.01) 0.85 (0.01) 0.99 (0.95 to 1.03)
Free T3 (pmol/l) 4.94 (0.14) 5.09 (0.15) 0.11 3.98 (0.23) 3.95 (0.22) 0.70 0.89 (0.01) 0.85 (0.01) 0.96 (0.92 to 0.99)
hCG (IU/l) 39051 (2539) 43637 (2837) 0.23 16132 (1290) 21116 (1688) 0.02 0.42 (0.04) 0.48 (0.04) 1.15 (0.91 to 1.46)
TSH=thyroid stimulating hormone; T4=thyroxine; T3=trriodothyronine; hCG=human chorionic gonadotrophin.
*Concentration units do not apply to ratios.
†Log transformed values were used for statistical testing of thyroid function tests and hCG concentration. Except for gestational age and hCG, statistical testing was done after adjustment
for age, body mass index, race (black people v others), smoking (current smoker or quit during pregnancy v never smoker or quit before pregnancy), log transformed hCG concentration, and
presence or absence of thyroid peroxidase antibodies above reference range.
‡Presented as arithmetic mean (standard deviation). Difference in gestational age between predelivery and baseline specimens was 148 (SD 25) days and 154 (30) days for cases and
controls, respectively (P=0.08). Two missing case specimens (one baseline, one predelivery) and their matched controls were excluded.
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quate iodine intake. A total of 92936 adults were eligi-
ble for the study, and 66140 (71.2%) participated. The
study has been described in detail elsewhere.
2223 A
non-fasting venous blood sample was requested from
each participant. Thyroid stimulating hormone con-
centrations were determined in samples of the study
population and included all women older than
40 years and a 5% random sample of women aged
20-40.
Linkage to medical birth registry of Norway
The unique 11 digit identification number of every
Norwegian citizen enabled linkage of parous women
toinformationinthemedicalbirthregistryofNorway.
Thisnationwideregistryhasrecordeddataonallbirths
inNorwaysince1967.Wethereforerestrictedtheana-
lysis to women who had had their first birth registered
during the period from 1967 until participation in the
Nord-Trondelag Health Study. Among women with a
measurement for thyroid stimulating hormone con-
centration, 7933 had had their first birth in 1967 or
later.Weexcludedwomenwithknownthyroiddisease
(n=695), twin or triplet first pregnancies (n=74), preg-
nancyatthetimethyroidstimulatinghormoneconcen-
tration was determined (n=33), and women without
information on smoking habits (n=10), leaving 7121
women for analysis. Thyroid peroxidase antibodies
were also measured in women with a thyroid stimulat-
ing hormone concentration greater than 4 mIU/l.
Criteria for pre-eclampsia used by the reporting
midwives and obstetricians have been in accordance
with the 1972 recommendations of the American Col-
lege of Obstetrics and Gynecologists.
24 These criteria
includeincreasedbloodpressureafter20weeks’gesta-
tion (≥140/90 mm Hg, or an increase in systolic blood
pressure of ≥30 mm Hg or in diastolic blood pressure
of ≥15 mm Hg), from measurements made before
20 weeks’ gestation, and proteinuria (≥0.3 g in a 24
hour urine specimen or a urine dipstick result of ≥+).
Procedures
Serum concentrations of thyroid stimulating hormone
weremeasuredattheHormoneLaboratory,AkerUni-
versity Hospital, Oslo, using DELFIA hTSH Ultra
(Wallac Oy, Turku, Finland). The coefficient of varia-
tion was less than 5%. The clinical reference range for
thyroid stimulating hormone in this population was
definedas0.50-3.50mIU/l.
25Thyroidperoxidaseanti-
bodies were also measured in people with concentra-
tions of thyroid stimulating hormone greater than 4
mIU/l (BRAHMS Diagnostica, Berlin, Germany).
Thosewithlevelsgreaterthan200IU/mlwereconsid-
eredtohavetestedpositiveforthyroidperoxidaseanti-
bodies.
Statistical analysis
We used multiple logistic regression analysis to deter-
mine odds ratios and 95% confidence intervals. All
analyseswereadjustedforageandsmokingstatus(cur-
rent, former, or never).
Results
Analyses were carried out among 7121 women with
thyroid stimulating hormone measurements who had
deliveredtheirfirstchildduringorafter1967,whenthe
medical birth registry of Norway was established
(table 3). Among women who had experienced pre-
eclampsia in their first pregnancy the probability of
havingserumthyroidstimulatinghormoneconcentra-
tions greater than the clinical reference range (>3.5
mIU/l) was higher than for women who did not
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Comparisons of differences in thyroid stimulating hormone (TSH)
concentration between predelivery and baseline specimens
across quarters of predelivery soluble fms-like tyrosine kinase 1
concentrations in normotensive controls and cases with pre-
eclampsia. |Soluble fms-like tyrosine kinase 1 concentrations
in normotensive controls were 1710-5620 pg/ml in the first
quarter, 5620-7554 pg/ml in the second quarter, 7554-
10789 pg/ml in the third quarter, and 10789-34907 pg/ml in
the fourth quarter. Differences in the arithmetic mean thyroid
stimulating hormone concentrations (mIU/l) for the first to
fourth quarters were, respectively, 0.01, 0.66 (P=0.006), 0.52
(P=0.03), and 0.92 (P<0.001), with P values indicated for
comparisons with the first quarter. Soluble fms-like tyrosine
kinase 1 concentrations in the cases with pre-eclampsia were
6620-13772 pg/ml in the first quarter, 13772-21282 pg/ml
in the second quarter, 21282-30740 pg/ml in the third
quarter, and 30740-82739 pg/ml in the fourth quarter.
Differences in the arithmetic mean thyroid stimulating
hormone concentrations (mIU/l) for the first to fourth quarters
were, respectively, 0.51, 0.94, 1.41 (P=0.003), and 1.33
(P=0.006), with significant P values indicated for comparisons
with the first quarter
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(adjusted odds ratio 1.7, 95% confidence interval 1.1
to 2.5). The mean number of years elapsed from deliv-
ery of the first pregnancy to the date of the thyroid
stimulating hormone measurement was 20.4 among
the women with pre-eclampsia in that pregnancy and
21.8yearsamongthewomenwithoutpre-eclampsiain
that pregnancy.
Thyroid peroxidase antibodies were also measured
in women with thyroid stimulating hormone concen-
trationsgreaterthan4.0mIU/l.Theassociationofpre-
eclampsia with subsequent hypothyroid function
(thyroidstimulatinghormone>4.0mIU/l)wasslightly
stronger in the absence of thyroid peroxidase anti-
bodies (adjusted odds ratio 2.6, 95% confidence inter-
val 1.3 to 5.0) than for hypothyroid function with
thyroidperoxidaseantibodies(1.8,1.0 to3.1;table 3).
Amongwomenwhohadexperiencedpre-eclampsiain
two pregnancies, the association with hypothyroid
function in the absence of thyroid peroxidase anti-
bodies was particularly strong (5.8, 1.3 to 25.5).
DISCUSSION
This study found that pre-eclampsia among nullipar-
ous women is associated with a greater subsequent
risk of subclinical hypothyroidism in pregnancy and
that women with a history of pre-eclampsia are at
greater risk of hypothyroid function many years after
pre-eclampsia.
The findings during pregnancy are consistent with
the results of previous studies
26-28 and indicate that
the increases in thyroid stimulating hormone concen-
trationduringpre-eclampsiaarenotrelatedtochanges
in circulating human chorionic gonadotrophin con-
centrations, a protein that stimulates the thyroid
gland and suppresses thyroid stimulating hormone.
19
In women with pre-eclampsia, but also in normoten-
sivecontrols,theextentofincreaseinthyroidstimulat-
ing hormone during pregnancy was directly related to
the magnitude of circulating soluble fms-like tyrosine
kinase 1 concentrations before delivery. This increase
was substantially greater in the pre-eclampsia group,
consistent with the suggestion that the effect of pre-
eclampsia on thyroid function may be mediated by
soluble fms-like tyrosine kinase 1.
Norwegian women who had experienced pre-
eclampsia in their first pregnancy were more likely
than other women to have concentrations of thyroid
stimulating hormone above the clinical reference
rangemanyyearsafterthepregnancy.Theassociation
wasstrongerifthehighconcentrationofthyroidstimu-
latinghormonewascombinedwithabsenceofthyroid
peroxidase antibodies, and particularly strong if pre-
eclampsia had occurred in two pregnancies. This sug-
gests that the hypothyroid function associated with
increased circulating concentrations of thyroid stimu-
lating hormone in pre-eclampsia may occur indepen-
dentoftheautoimmunemechanismsthataregenerally
accepted as the most likely cause of subclinical and
overt hypothyroidism in iodine replete women.
2930
The clinical syndrome of pre-eclampsia has been
hypothesised to result from excessive release of anti-
angiogenic proteins—most notably soluble fms-like
tyrosine kinase 1—from the placenta into maternal
blood, resulting in an antiangiogenic state with low
levels of free placental growth factor and free vascular
endothelial growth factor.
831Administration of vascu-
lar endothelial growth factor inhibitors such as soluble
fms-liketyrosinekinase1torodentsinduceshyperten-
sion, proteinuria, and glomerular endotheliosis, the
hallmarks of pre-eclampsia. The particular sensitivity
of glomerular capillaries to reduced levels of vascular
endothelial growth factor may be attributed to their
fenestrated endothelium, which requires the constitu-
tive expression of vascular endothelial growth factor
by renal podocytes for health and function.
32 Thyroid
capillaries also have a fenestrated endothelium.
15 In
mice, two weeks’ exposure to exogenous soluble fms-
like tyrosine kinase 1 or to other vascular endothelial
growthfactorinhibitorsresultedinareductionofthyr-
oidtissuecapillarydensitybytwothirdsandincreased
thyroid stimulating hormone concentration. Stopping
soluble fms-like tyrosine kinase 1 from being adminis-
tered led to a nearly complete recovery after three
weeks.
15 This seems to be analogous to the recovery
from hypertension and proteinuria in experimental
animals after stopping inhibition of vascular endo-
thelialgrowthfactorandinwomenwithpre-eclampsia
after delivery of the placenta.
710Together with reports
of hypothyroidism in patients with cancer treated with
Table 3 |Odds ratios for thyroid stimulating hormone (TSH) concentrations above the reference range (>3.5 mIU/l), and for high TSH concentrations (≥4.0
mIU/l) with positive (>200 IU/ml) or negative (≤200 IU/ml) results for thyroid peroxidase (TPO) antibody status, according to pre-eclampsia status in
previous singleton pregnancies
Variables
TSH concentration >3.5 mIU/l
TSH concentration >4.0 mIU/l,
TPO antibodies >200 IU/ml
TSH concentration >4.0 mIU/l,
TPO antibodies ≤200 IU/ml
Yes/No Odds ratio (95% CI) Yes/No Odds ratio (95% CI) Yes/No Odds ratio (95% CI)
Women with ≥1 pregnancies:
No pre-eclampsia in first pregnancy 407/6444 1.0 (Reference) 188/6651 1.0 (Reference) 89/6750 1.0 (Reference)
Pre-eclampsia in first pregnancy 29/241 1.7 (1.1 to 2.5) 14/255 1.8 (1.0 to 3.1) 10/259 2.6 (1.3 to 5.0)
Women with ≥2 pregnancies:
No pre-eclampsia in first or second pregnancy 350/5532 1.0 (Reference) 167/5704 1.0 (Reference) 72/5799 1.0 (Reference)
Pre-eclampsia in first or second pregnancy 24/270 1.3 (0.9 to 2.1) 12/281 1.4 (0.8 to 2.5) 8/285 2.2 (1.0 to 4.6)
Pre-eclampsia in first and second pregnancy 4/21 2.5 (0.9 to 7.5) 2/23 2.6 (0.6 to 11.3) 2/23 5.8 (1.3 to 25.5)
Odds ratios are adjusted for age and smoking status at Nord-Trondelag Health Study examination.
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inhibitors,
11-15 the evidence suggests that high levels
of exposure to soluble fms-like tyrosine kinase 1 as in
pre-eclampsia may be associated with increased risk
for reduced thyroid function during and after preg-
nancy.
Aswomenwithsubclinicalthyroiddysfunctionareat
greater risk of progression to overt hypothyroidism,
33
our findings could have important implications for the
subsequent care of women with pre-eclampsia. Not
only should they be followed closely for the develop-
mentofcardiovascularandrenaldiseaseandtheameli-
oration of predisposing risk factors, but consideration
shouldalsobegiventomonitoringforthedevelopment
of reduced thyroid function and clinically important
hypothyroidism.Althoughtheabsoluteriskforreduced
thyroid function and the future development of
hypothyroidism in these women seems to be low, the
availability of low cost thyroxine replacement therapy
makes early treatment of hypothyroidism an attractive
option that may substantially reduce the associated
morbidity and improve quality of life. Moreover,
untreatedhypothyroidismmaybeamodifiableriskfac-
tor for cardiovascular disease; and its treatment might
prevent early cardiovascular disease in women with a
history of pre-eclampsia.
23
Our study raises several questions: Is there a contri-
butionofhypothyroidfunctiontotheexcessofcardio-
vascular disease in women with a history of pre-
eclampsia? Does subclinical hypothyroidism in
women with pre-eclampsia have adverse effects on
the long term health of the children?
3435Does the risk
of subclinical and overt hypothyroidism in women
with pre-eclampsia increase with time elapsed after
pregnancy? Are women who have had multiple nor-
mal pregnancies or pregnancies with multiple fetuses
at greater risk of hypothyroidism because of the
increased levels of soluble fms-like tyrosine kinase 1
in pregnancies with multiple fetuses and in normal
pregnanciesatterm?Thelatterpossibilityissupported
by our finding that soluble fms-like tyrosine kinase 1
concentration is positively associated with thyroid sti-
mulating hormone concentration in normotensive
pregnancies as well.
In summary,increased circulating concentrations of
soluble fms-like tyrosine kinase 1, most notably after
onset of pre-eclampsia, were associated with subtle
abnormalities of the thyroid during pregnancy. These
in turn may predispose to the development of reduced
thyroidfunctionandpossiblyoverthypothyroidismin
later life.
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